The Evolving Role of Medical Affairs in Product Launch: Role, Collaboration and Digital Use

STUDY OVERVIEW

The last decade has seen Medical Affairs move from a support function to a strategic, central function in biopharma. Change has been constant with Medical becoming the hub for insight and intelligence for the company, taking the lead in shaping the evidence agenda, establishing excellence in external engagement and value communication. Additionally, the Covid-19 pandemic has triggered a tsunami of rapid digital technological adoptions for Medical Affairs.

This research explores Medical’s role in product launch. The research probes digital tool utilization and launch tool deployment, roles and responsibilities, and cross-functional alignment.

KEY TOPICS

• Executive Summary: Methodology, Participants, & Key Findings
• Launch Excellence and Medical’s Role & Activity Effectiveness
• Ensuring Cross-functional Alignment and Collaboration
• Adopting to Ongoing Changes in Medical Landscape

KEY METRICS

• What role does your Medical Affairs group play at launch?
• What role does your Medical Affairs group play at launch in the following areas?
• How effective is your Medical Affairs organization in regards to these activities for a successful launch?
• How effective is your Medical Affairs organization in regards to these activities for a successful launch?
• How does your Medical Affairs work with internal colleagues to ensure successful launch?
• What is the role of your Medical Affairs group in cross-functional launch teams?
• In your experience with digital technologies, how has the role of Medical Affairs in launch changed within the last 3 years?
  

• Roles: Expand Medical’s education strategy pre-launch, partnering closely with Commercial to align activities and address gaps; proactive educational events such as classic symposiums and MSL education on disease state are needed areas of improvement for Medical.

The study engaged 60 executives from 43 leading life sciences companies. Medical Directors and VPs represent nearly four-fifths of the leaders who shared data and insights on Medical launch activities in this study

Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Biopharmaceutical; Diagnostic; Health Care; Chemical; Consulting; Consumer Products; Clinical Research; Laboratories; Science


Companies Profiled:
Adamas Pharmaceuticals; AstraZeneca; Alcon; Albireo; Apellis Pharmaceuticals; ASC Therapeutics; Baxter Healthcare; BELLUS Health; Boehringer Ingelheim; BIAL; bioMerieux; Cardinal Health; Cipla; Eisai; EMD Serono; Genentech; Fidia; Eurofarma; GlaxoSmithKline ; GW Pharmaceuticals; Ipsen; Helsinn; Karyopharm Therapeutics; Kyowa Kirin; Labaid Group; Matinas BioPharma; Lundbeck; MEDiSTRAVA; Melinta Therapeutics; Inc; Merck Serono; NextGen Healthcare; Novartis; Pfizer; Pixacore; Gedeon Richter ; Sandoz; Sanofi; Santen; Sunovion; Takeda Pharmaceuticals; Thermo Fisher; Terumo Corporation; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.